The Brain Drug Startup That Convinced Wall Street to Bet $255M on Crazy

What They're Actually Building

Seaport's secret sauce is something called the Glyph platform. Think of it like a molecular delivery trick: the company takes known brain-active compounds (drugs that already work but have problems getting into the body efficiently) and redesigns them as "prodrugs" with better oral absorption and less liver toxicity.

Three programs sit in the pipeline:

GlyphAllo (SPT-300) is their lead candidate, an oral version of allopregnanolone for major depressive disorder. It entered a Phase 2b trial in July 2025 and is still enrolling. IPO funds will push it toward Phase 3.

GlyphAgo (SPT-320) targets generalized anxiety disorder. In April 2026, the company reported that their version showed a 6.8-fold improvement in bioavailability compared to the unmodified drug. Two trials are next: a Phase 2a study on sleep benefits in anxiety patients and a larger Phase 2b registration-enabling trial.

Glyph2BLSD (SPT-348) is the wildcard. It's a prodrug version of non-hallucinogenic 2-bromo-LSD, aimed at treatment-resistant depression, PTSD, and headache disorders. Still preclinical, still early, still fascinating.

Why Investors Showed Up Now

The broader biotech IPO market in 2026 has been a paradox: fewer deals, but much bigger ones. Ten biotechs priced IPOs in Q1, collectively raising around $1.7 billion. The median raise in Q1 hit $287.5 million, the highest since 2021.

But here's what makes Seaport's debut remarkable. Those other big IPOs? Kailera ($625 million), Aktis Oncology ($318 million), Eikon ($381 million): they're in oncology, immunology, or platform therapeutics. The "safe" bets. Nobody else has tested investor appetite for CNS drugs this year.

For years, CNS biotech funding cratered. Investors fled to oncology and immunology where success rates were higher and timelines shorter. The neuropsychiatry sector became biotech's haunted house; everyone knew what was inside, and nobody wanted to go in.

The Tide May Be Turning

Several forces are pulling investors back toward the brain. AI-driven drug discovery companies claim they can fix the problems that killed previous CNS programs: poor patient selection, bad biomarkers, flawed trial designs. GLP-1 drugs (the weight-loss blockbusters) are showing unexpected neuropsych benefits in Parkinson's and depression studies. Precision medicine approaches are advancing in neurodegenerative diseases.

Seaport's approach sidesteps the biggest graveyard (novel targets with unknown biology) by taking proven compounds and solving their delivery problems instead. It's a lower-risk bet wrapped in a high-risk category. Investors seem to appreciate the distinction.

The Scoreboard

A strong valuation on day one. A 10% pop on debut. The first neuropsychiatry IPO of the year, in a market that's been allergic to brain drugs for half a decade.

None of this guarantees Seaport's drugs will work. Phase 2 data for GlyphAllo hasn't read out yet. The anxiety program still needs to prove itself in larger trials. And the LSD-derived compound is years from human testing.

But Wall Street just made a $255 million bet that Daphne Zohar can do for Seaport what she did for Karuna. Given that Karuna's buyers paid $14 billion, the math doesn't seem crazy. It seems calculated.